Seguridad y aceptabilidad del sistema intrauterino liberador de levonorgestrel 52 mg en mujeres con hemorragia uterina anormal en un centro de atención ambulatoria en Bogotá, Colombia, 2012-2016

Palabras clave: menorragia, dispositivos intrauterinos, levonorgestrel, hemorragia uterina

Resumen

Objetivo: describir la seguridad y aceptabilidad del uso del sistema intrauterino liberador de levonorgestrel de 52 mg en mujeres con hemorragia uterina anormal. Materiales y métodos: cohorte retrospectiva en la que se incluyeron mujeres de 18 años o más con diagnóstico de hemorragia uterina anormal, reporte por ultrasonido de tamaño uterino entre 6 y 10 cm de longitud y cavidad endometrial uniforme en toda su longitud, independiente de alteración estructural, a quienes se les colocó para tratamiento el sistema intrauterino liberador de levonorgestrel de 52 mg, en el periodo de 2012 hasta 2016. Se realizó un muestreo por conveniencia. Se midieron variables sociodemográficas y clínicas basales, así como la percepción de la hemorragia por parte de la paciente y la frecuencia de falla, amenorrea, necesidad de histerectomía y eventos adversos, con seguimiento a 12 meses. Se aplicó estadística descriptiva. Resultados: se evaluaron 200 pacientes, hubo una percepción de mejoría subjetiva del volumen de sangrado y de la frecuencia de incapacidad laboral o asistencia a urgencias. El 90% de las pacientes registró amenorrea y el 6% eventos adversos. Conclusiones: el sistema intrauterino liberador de levonorgestrel de 52 mg es una alternativa segura para el manejo de la hemorragia uterina anormal en mujeres con úteros de tamaño normal y sin alteraciones submucosas del endometrio. Se requieren estudios aleatorizados en el medio local para evaluar su efectividad y eficiencia respecto a otras alternativas de manejo.

Descargas

La descarga de datos todavía no está disponible.

Referencias bibliográficas

Munro MG, Critchley HOD, Broder MS, Fraser IS, FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113(1):3-13. https://doi.org/10.1016/j.ijgo.2010.11.011

Munro MG, Critchley HOD, Fraser IS, Haththotuwa R, Kriplani A, Bahamondes L, et al. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynecol Obstet. 2018;143(3):393-408. https://doi.org/10.1002/ijgo.12666

Spencer CP, Whitehead MI. Endometrial asessment re-visited. BJOG An Int J Obstet Gynaecol. 1999;106(7):623-32. https://doi.org/10.1111/j.1471-0528.1999.tb08358.x

Fraser IS, Critchley HOD, Munro MG, Broder M. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril. 2007;87(3):466-76. https://doi.org/10.1016/j.fertnstert.2007.01.023

Fraser IS, Critchley HOD, Munro MG, Broder M. Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Hum Reprod. 2007;22(3):635-43. https://doi.org/10.1093/humrep/del478

Munro MG, Critchley HOD, Fraser IS. Research and clinical management for women with abnormal uterine bleeding in the reproductive years: More than PALM-COEIN. BJOG An Int J Obstet Gynaecol. 2017;124(2):185-9. https://doi.org/10.1111/1471-0528.14431

National Institute for Health and Care Excellence (NICE). Heavy menstrual bleeding: Assessment and management. NG88; March 2018. Disponible en: https://www.nice.org.uk/guidance/ng88.

Xiao B, Wu S-C, Chong J, Zeng T, Han L-H, Luukkainen T. Therapeutic effects of the levonorgestrelreleasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril. 2003;79(4):963-9. https://doi.org/10.1016/s0015-0282(02)04913-0

Munro MG, Mainor N, Basu R, Brisinger M, Barreda L. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: A randomized controlled trial. Obstet Gynecol. 2006;108(4):924-9. https://doi.org/10.1097/01.AOG.0000238343.62063.22

James AH, Kouides PA, Abdul-Kadir R, Dietrich JE, Edlund M, Federici AB, et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: Consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol. 2011;158(2):124-34. https://doi.org/10.1016/j.ejogrb.2011.04.025

Bofill Rodriguez M, Lethaby A, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;9:CD000400. https://doi.org/10.1002/14651858.CD000400.pub4

ACOG. Committee opinion: Management of acute AUB in nonpregnant re-productive aged women. Obstet Gynecol. 2014;123(603):1403-7.

Bayer AG, Berlin G. Mirena Annotated CCDS 2014; 2014.

Phillips V, Graham CT, Manek S, McCluggage WG. The effects of the levonorgestrel intrauterine system (Mirena coil) on endometrial morphology. J Clin Pathol. 2003;56(4):305-7. https://doi.org/10.1136/jcp.56.4.305

Bayer HealthCare Pharmaceuticals Inc. Mirena® (levonorgestrel- releasing intrauterine system) prescribing information. 2014;1-193.

Beatty MN, Blumenthal PD. The levonorgestrelreleasing intrauterine system: Safety, efficacy, and patient acceptability. Ther Clin Risk Manag. 2009/08/03. 2009;5(1):561-74. https://doi.org/10.2147/tcrm.s5624

Bofill Rodriguez M, Lethaby A, Jordan V. Progestogenreleasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2020;6:CD002126. https://doi.org/10.1002/14651858.CD002126.pub4

Espey E. Levonorgestrel intrauterine system—firstline therapy for heavy menstrual bleeding. N Engl J Med. 2013;368(2):184-5. https://doi.org/10.1056/NEJMe1214191

Benetti-Pinto CL, De Sá Rosa-E-Silva ACJ, Yela DA, Júnior JMS. Sangramento uterino anormal. Rev Bras Ginecol Obstet. 2017;39(7):358-68. https://doi.org/10.1055/s-0037-1603807

Yuk JS, Song JY, Lee JH, Park WI, Ahn HS, Kim HJ. Levonorgestrel-Releasing Intrauterine Systems versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A meta-analysis. Ann Surg Oncol. 2017;24(5):1322-9. https://doi.org/10.1245/s10434-016-5699-9.

Food and Drug Administration (FDA). Center for Drug evaluation and research. Application number: NDA 021225 S-031.

Costescu DJ. Levonorgestrel-releasing intrauterine systems for long-acting contraception: Current perspectives, safety, and patient counseling. Int J Womens Health. 2016;8:589-598. https://doi.org/10.2147/IJWH.S9970522.

d’Arcangues C. Worldwide use of intrauterine devices for contraception. Contraception. 2007;75(6 Suppl):S2-7. https://doi.org/10.1016/j.contraception.2006.12.024

Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril. 2003; 79(5):1194-8. https://doi.org/10.1016/S0015-0282(03)00175-4.

Magalhães J, Aldrighi JM, de Lima GR. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception. 2007;75(3):193-8. https://doi.org/10.1016/j.contraception.2006.11.004

Murat Naki M, Tekcan C, Ozcan N, Cebi M. Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumes. Fertil Steril. 2010;94(1):371-4. https://doi.org/10.1016/j.fertnstert.2009.09.048

Gunes M, Ozdegirmenci O, Kayikcioglu F, Haberal A, Kaplan M. The Effect of Levonorgestrel Intrauterine System on Uterine Myomas: A 1-Year Follow-up Study. J Minim Invasive Gynecol. 2008;15(6):735-8. https://doi.org/10.1016/j.jmig.2008.08.011

Ozdegirmenci O, Kayikcioglu F, Akgul MA, Kaplan M, Karcaaltincaba M, Haberal A, et al. Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil Steril. 2011;95(2):497-502. https://doi.org/10.1016/j.fertnstert.2010.10.009

Heikinheimo O, Gemzell-Danielsson K. Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS). Acta Obstet Gynecol Scand. 2012;91(1):3-9. https://doi.org/10.1111/j.1600-0412.2011.01303.x

Desai R. Efficacy of levonorgestrel releasing intrauterine system for the treatment of menorrhagia due to benign uterine lesions in perimenopausal women. J Midlife Health. 2012;3(1):20. https://doi.org/10.4103/0976-7800.98812

Lahteenmaki P, Haukkamaa M, Puolakka J, Riikonen U, Sainio S, Suvisaari J, et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. Br Med J. 1998;316(7138):1122-6. https://doi.org/10.1136/bmj.316.7138.1122

Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2003;(2):CD003855. https://doi.org/10.1002/14651858.cd003855

Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivelä A, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: Randomized trial 5-year follow-up. J Am Med Assoc. 2004;291(12):1456-63. https://doi.org/10.1001/jama.291.12.1456

Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol. 1991;164(3):879-83. https://doi.org/10.1016/S0002-9378(11)90533-X

Endrikat J, Shapiro H, Lukkari-Lax E, Kunz M, Schmidt W, Fortier M. A canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Canada. 2009;31(4):340-7. https://doi.org/10.1016/S1701-2163(16)34151-2

Marions L, Lövkvist L, Taube A, Johansson M, Dalvik H, Øverlie I. Use of the levonorgestrel releasingintrauterine system in nulliparous women—a noninterventional study in Sweden. Eur J Contracept Reprod Heal Care. 2011;16(2):126-34. https://doi.org/10.3109/13625187.2011.558222

Heikinheimo O, Lehtovirta P, Aho I, Ristola M, Paavonen J. The levonorgestrel-releasing intrauterine system in human immunodeficiency virusinfected women: Z 5-year follow-up study. Am J Obstet Gynecol. 2011;204(2):126.e1-126.e4. https://doi.org/10.1016/j.ajog.2010.09.002

Rogovskaya S, Rivera R, Grimes DA, Chen PL, Pierre-Louis B, Prilepskaya V, et al. Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: A randomized trial. Obstet Gynecol. 2005;105(4):811-5. https://doi.org/10.1097/01.AOG.0000156301.11939.56

Lukes AS, Reardon B, Arepally G. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. Fertil Steril. 2008;90(3):673-7. https://doi.org/10.1016/j.fertnstert.2007.07.1315

Publicado
2020-09-07
Cómo citar
1.
Sandoval-Vivas P. Seguridad y aceptabilidad del sistema intrauterino liberador de levonorgestrel 52 mg en mujeres con hemorragia uterina anormal en un centro de atención ambulatoria en Bogotá, Colombia, 2012-2016. Rev. Colomb. Obstet. Ginecol. [Internet]. 7 de septiembre de 2020 [citado 24 de octubre de 2020];71(3):247-56. Disponible en: https://revista.fecolsog.org/index.php/rcog/article/view/3547
Sección
Investigación Original